港股異動丨福祿控股(2101.HK)漲4.73% 基於SaaS的增值服務佔總收入比例不斷提升
格隆匯1月20日丨去年9月上市的次新股福祿控股(2101.HK)漲4.73%,報7.08港元,總市值28億港元。福祿控股是中國規模最大的虛擬商品及服務提供商,通過SaaS技術平台——福祿開放平台,連接虛擬商品提供商、消費場景和消費者。數據顯示,2018年時,福祿控股開始為客户提供基於SaaS的增值服務,當年所產生的收入佔比為0.4%。至2019年,增值服務收入同比大增2742.6%至2168.9萬元人民幣,佔總收入的比例提升至9%。數據顯示,截止2020年上半年,福祿控股的增值服務收入達到3629萬元,同比增長1121%,佔總收入比例已提升至22.8%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.